Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDBethesda (MD)GOLD2018
   Google Scholar
• SaettaMFinkelsteinRCosioMGMorphological and cellular basis for airflow limitation in smokersEur Respir J199478150515157957838
   PubMed Web of Science ®Google Scholar
• FinkelsteinRFraserRSGhezzoHCosioMGAlveolar inflammation and its relation to emphysema in smokersAm J Respir Crit Care Med19951525 Pt 1166616727582312
   PubMed Web of Science ®Google Scholar
• ThompsonABMuellerMBHeiresAJAerosolized beclomethasone in chronic bronchitis: improved pulmonary function and diminished airway inflammationAm Rev Respir Dis199214623893951489129
   PubMed Web of Science ®Google Scholar
• ConfalonieriMMainardiEdella PortaRInhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary diseaseThorax19985375835859797758
   PubMed Web of Science ®Google Scholar
• PaggiaroPLDahleRBakranIFrithLHollingworthKEfthimiouJMulticentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary diseaseLancet199835191057737809519948
   PubMed Web of Science ®Google Scholar
• WiseRConnettJWeinmannGScanlonPSkeansMEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• PauwelsRALöfdahlC-GLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smokingN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• VestboJSørensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• HighlandKBStrangeCHeffnerJELong-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysisAnn Intern Med20031381296997312809453
   PubMed Web of Science ®Google Scholar
• SorianoJBSinDDZhangXA pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placeboChest2007131368268917356080
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEKileyJPEffects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health StudyJAMA199427219149715057966841
   PubMed Web of Science ®Google Scholar
• SinDDMcAlisterFAManSFAnthonisenNRContemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA2003290172301231214600189
   PubMed Web of Science ®Google Scholar
• AgarwalRAggarwalANGuptaDJindalSKInhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trialsChest2010137231832519783669
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD002991
   PubMed Web of Science ®Google Scholar
• BarnesPJShapiroSDPauwelsRAChronic obstructive pulmonary disease: molecular and cellular mechanismsEur Respir J200322467268814582923
   PubMed Web of Science ®Google Scholar
• BarnesPJImmunology of asthma and chronic obstructive pulmonary diseaseNat Rev Immunol20088318319218274560
   PubMed Web of Science ®Google Scholar
• ChengSLSuKCWangHCPerngDWYangPCChronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumoniaDrug Des Devel Ther20148601607
   Web of Science ®Google Scholar
• BoardmanCChachiLGavrilaAMechanisms of glucocorticoid action and insensitivity in airways diseasePulm Pharmacol Ther201429212914325218650
   PubMed Web of Science ®Google Scholar
• PowellHGibsonPGHigh dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and childrenCochrane Database Syst Rev200422CD004109
   Google Scholar
• FoodUSAdministrationDrugChronic obstructive pulmonary disease: developing drugs for treatment2016 Available from: https://www.gpo.gov/fdsys/pkg/FR-2016-05-20/pdf/2016-11855.pdfAccessed July 12, 2018
   Google Scholar
• UsmaniOSItoKManeechotesuwanKGlucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapyAm J Respir Crit Care Med2005172670471215860753
   PubMed Web of Science ®Google Scholar
• HaqueRHakimAMoodleyTInhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPDJ Allergy Clin Immunol201313251166117324070494
   PubMed Web of Science ®Google Scholar
• BarnesPJScientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroidsEur Respir J200219118219111843317
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 µg) or salmeterol (50 µg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting β2-agonist in one inhaler versus long-acting β2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD006829
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJKestertonACombined corticosteroid and long-acting β2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20138CD006826
   PubMed Web of Science ®Google Scholar
• ObaYLoneNAComparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysisInt J Chron Obstruct Pulmon Dis2014946947924872685
   PubMed Web of Science ®Google Scholar
• MiravitllesMD’UrzoASinghDKoblizekVPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewRespir Res201617111227613392
   PubMed Web of Science ®Google Scholar
• CalverleyPMErikssonGJenkinsCREarly efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPDInt J Chron Obstruct Pulmon Dis201712132528031707
   PubMed Web of Science ®Google Scholar
• CalverleyPMPostmaDSAnzuetoAREarly response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbationsInt J Chron Obstruct Pulmon Dis20161138139026952309
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• TrudoFKernDMDavisJRComparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatmentsInt J Chron Obstruct Pulmon Dis2015102055206626451101
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• RodrigoGJPriceDAnzuetoALABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis20171290792228360514
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• BafadhelMMcKennaSTerrySBlood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trialAm J Respir Crit Care Med20121861485522447964
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• BafadhelMPetersonSde BlasMAPredictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trialsLancet Respir Med20186211712629331313
   PubMed Web of Science ®Google Scholar
• TashkinDPWechslerMERole of eosinophils in airway inflammation of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20181333534929403271
   PubMed Web of Science ®Google Scholar
• ChengSLLinCHEffectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic countsInt J Chron Obstruct Pulmon Dis2016112341234827703344
   PubMed Web of Science ®Google Scholar
• CalverleyPVliesBA rational approach to single, dual and triple therapy in COPDRespirology201621458158926611377
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• HastieATMartinezFJCurtisJLAssociation of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohortLancet Respir Med201751295696729146301
   PubMed Web of Science ®Google Scholar
• ChristensonSASteilingKvan den BergeMAsthma-COPD overlap: clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015191775876625611785
   PubMed Web of Science ®Google Scholar
• TamadaTSugiuraHTakahashiTBiomarker-based detection of asthma-COPD overlap syndrome in COPD populationsInt J Chron Obstruct Pulmon Dis2015102169217626491283
   PubMed Web of Science ®Google Scholar
• AlshabanatAZafariZAlbanyanODairiMFitzgeraldJMAsthma and COPD overlap syndrome (ACOS): a systematic review and meta analysisPLoS One2015109e013606526336076
   PubMed Web of Science ®Google Scholar
• TashkinDPMurrayRPSmoking cessation in chronic obstructive pulmonary diseaseRespir Med2009103796397419285850
   PubMed Web of Science ®Google Scholar
• SimmonsMSConnettJENidesMASmoking reduction and the rate of decline in FEV1: results from the Lung Health StudyEur Respir J20052561011101715929955
   PubMed Web of Science ®Google Scholar
• TamimiASerdarevicDHananiaNAThe effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implicationsRespir Med2012106331932822196881
   PubMed Web of Science ®Google Scholar
• HoonhorstSJten HackenNHVonkJMSteroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokersPLoS One201492e8744324505290
   PubMed Web of Science ®Google Scholar
• SohalSSReidDSoltaniAChanges in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trialPLoS One201385e6483323717666
   PubMed Web of Science ®Google Scholar
• van OverveldFJDemkowUGóreckaDde BackerWAZielińskiJDifferences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPDJ Physiol Pharmacol200657Suppl 427328217072055
   PubMed Web of Science ®Google Scholar
• TashkinDPMurrayHESkeansMMurrayRPSkin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study IIChest200412641123113315486373
   PubMed Web of Science ®Google Scholar
• EichenhornMSWiseRAMadhokTCLack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study IIChest20031241576212853502
   PubMed Web of Science ®Google Scholar
• CummingRGMitchellPLeederSRUse of inhaled corticosteroids and the risk of cataractsN Engl J Med199733718149203425
   PubMed Web of Science ®Google Scholar
• WangJJRochtchinaETanAGCummingRGLeederSRMitchellPUse of inhaled and oral corticosteroids and the long-term risk of cataractOphthalmology2009116465265719243828
   PubMed Web of Science ®Google Scholar
• MillerDPWatkinsSESampsonTDavisKJLong-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research DatabaseInt J Chron Obstruct Pulmon Dis2011646747622003292
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• SilvaDRCoelhoACDumkeAOsteoporosis prevalence and associated factors in patients with COPD: a cross-sectional studyRespir Care201156796196821352667
   PubMed Web of Science ®Google Scholar
• FergusonGTCalverleyPMAAndersonJAPrevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health studyChest200913661456146519581353
   PubMed Web of Science ®Google Scholar
• LokeYKCavallazziRSinghSRisk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studiesThorax201166869970821602540
   PubMed Web of Science ®Google Scholar
• ScanlonPDConnettJEWiseRALoss of bone density with inhaled triamcinolone in Lung Health Study IIAm J Respir Crit Care Med2004170121302130915374846
   PubMed Web of Science ®Google Scholar
• RommeEAGeusensPLemsWFFracture prevention in COPD patients: a clinical 5-step approachRespir Res2015163225848824
   PubMed Web of Science ®Google Scholar
• BourbeauJAaronSDBarnesNCDavisKJLacasseYNadeauGEvaluating the risk of pneumonia with inhaled corticosteroids in COPD: retrospective database studies have their limitations SARespir Med2017123949728137503
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPLoS One201495e9714924878543
   PubMed Web of Science ®Google Scholar
• SinghSAminAVLokeYKLong-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysisArch Intern Med2009169321922919204211
   PubMed Web of Science ®Google Scholar
• SinDDTashkinDZhangXBudesonide and the risk of pneumonia: a meta-analysis of individual patient dataLancet2009374969171271919716963
   PubMed Web of Science ®Google Scholar
• JansonCLarssonKLisspersKHPneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)BMJ2013346f330623719639
   PubMed Web of Science ®Google Scholar
• MorjariaJBRigbyAMoriceAHInhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT studyLung2017195328128828255905
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
   PubMed Web of Science ®Google Scholar
• JansonCStratelisGMiller-LarssonAHarrisonTWLarssonKScientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPDInt J Chron Obstruct Pulmon Dis2017123055306429089754
   PubMed Web of Science ®Google Scholar
• YangHHLaiCCWangYHSevere exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting β2 agonistInt J Chron Obstruct Pulmon Dis2017122477248528860742
   PubMed Web of Science ®Google Scholar
• SinghDMiravitllesMVogelmeierCChronic obstructive pulmonary disease individualized therapy: tailored approach to symptom managementAdv Ther201734228129927981495
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• KwakMSKimEJangEJKimHJLeeCHThe efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methodsInt J Chron Obstruct Pulmon Dis2015102365237626604734
   PubMed Web of Science ®Google Scholar
• MäkeläMJBackerVHedegaardMLarssonKAdherence to inhaled therapies, health outcomes and costs in patients with asthma and COPDRespir Med2013107101481149023643487
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• SimeoneJCLuthraRKailaSInitiation of triple therapy maintenance treatment among patients with COPD in the USInt J Chron Obstruct Pulmon Dis201712738328053518
   PubMed Web of Science ®Google Scholar
• ManninoDYuTCZhouHHiguchiKEffects of GOLD-adherent prescribing on COPD symptom burden, exacerbations, and health care utilization in a real-world settingChronic Obstr Pulm Dis20152322323528848845
   PubMedGoogle Scholar
• Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) [package insert]Research Triangle Park (NC)GlaxoSmithKline2017
   Google Scholar
• National Institute for Health and Care ExcellenceChronic Obstructive Pulmonary Disease: Management of Adults With Chronic Obstructive Pulmonary Disease in Primary and Secondary CareLondonNICE2009
   Google Scholar
• HanMKQuibreraPMCarrettaEEFrequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohortLancet Respir Med20175861962628668356
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• PavordIDChanezPCrinerGJMepolizumab for eosinophilic chronic obstructive pulmonary diseaseN Engl J Med2017377171613162928893134
   PubMed Web of Science ®Google Scholar
• AstraZenecaAstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease [press release]2018511 Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.htmlAccessed July 12, 2018
   Google Scholar
• AstraZenecaUpdate on TERRANOVA Phase III trial for Fasenra in chronic obstructive pulmonary disease [press release]2018530 Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.htmlAccessed July 12, 2018
   Google Scholar